Clinical Trial Update: Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy as monotherapy for intermediate-risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING